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Abstract
Background: Increased level of serum S100B can serve as a marker of metastatic spread in patients with
cutaneous melanoma (CM). In patients with elevated S100 B and/or clinical signs of disease progression PET-CT
scan is a valuable tool for discovering metastases and planning treatment.
The aims of this study were to determine whether regular measurements of serum S100B are a useful tool for
discovering patients with CM metastases and to evaluate the diagnostic value of PET-CT during the follow-up.
Methods: From September 2007 to February 2010, 115 CM patients included in regular follow up at the Institute
of Oncology Ljubljana were appointed to PET-CT. There were 82 (71.3%) patients with clinical signs of disease
progression and 33 (28.7%) asymptomatic patients with two subsequent elevated values of S100B. Sensitivity,
specificity, positive and negative predictive value (PPV, NPV) of S100B and PET-CT were calculated using standard
procedures.
Results: Disease progression was confirmed in 81.7% of patients (in 86.5% of patients with clinical signs of disease
progression and in 69.7% of asymptomatic patients with elevated S100B). Sensitivity, specificity, PPV and NPV of
S100B was 33.8%, 90.9%, 96.0% and 17.5% in patients with clinical signs of disease progression. In 20.0% of patients
increased serum S100B was the only sign of disease progression. Sensitivity and PPV of S100 in this group of
patients were 100.0% and 69.7%.
With PET-CT disease progression was diagnosed in 84.2% of symptomatic patients and in 72.7% of asymptomatic
patients with elevated S100B. The sensitivity, specificity, PPV and NPV of PET-CT for symptomatic patients was
98.5%, 90.9%, 98.5% and 90.9% and 100%, 90.0%, 95.8% and 100% for asymptomatic patients with elevated S100.
Conclusions: Measurements of serum S100B during regular follow-up of patients with CM are a useful tool for
discovering disease progression in asymptomatic patients. The value of its use increases if measurements are
followed by extended whole body PET-CT.
Background
The prognosis of patients with cutaneous melanoma
(CM) is determined by histology of the primary tumour
and by the presence and extent of metastatic disease.
Available laboratory, radiographic and nuclear medicine
techniques are important components of patient evalua-
tion but their usefulness is being constantly questioned
by clinicians.
During the last decade many CM associated blood
compounds have been examined including melanoma
associated antigens, cytokines, metalloproteinase, angio-
genesis factor and others. Of all these compounds, S100
is at the moment the only widely applied CM biomarker
[1]. More than 20 years ago, it was first demonstrated
that melanoma cells can secrete a soluble form of S100
protein [2]. The term S100 refers to members of a mul-
tigene family of low-molecular-weight (9-13 kDa) cal-
cium -modulated proteins [1]. The first one was
originally isolated from the bovine brain tissue and
named after its solubility in 100% saturated ammonium
sulphate solution at neutral pH [1,3]. Currently there
are 20 known members of structurally related and inter-
acting proteins [4]. Two subunits S100 A and S100 B
have the ability to form homodimers, heterodimers and
oligodimers and are widely distributed in the peripheral
and central nervous system but can be also expressed by
cells such are chondrocytes, adipocytes and melanocytes.
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activities such as signal transduction path, cell differen-
tiation, motility, transcription and cell cycle progression
[1].
S100B, formed by two B or A and B subunits, is cur-
rently best-studied CM biomarker. Increased serum
levels of S100B are associated with presence of metas-
tases and are described to correlate with reduced survi-
val. They reflect tumour load, stage and prognosis and
are believed to be an independent poor prognostic fac-
tor in CM [3]. Findings published by Mocellin even
proved, that this serum marker influences patients survi-
val independently of the TNM staging system [5]. S100B
has also been used as a valuable marker in assessing
patient’s response to treatment [3]. Unfortunately abnor-
mal circulating levels can also be found in liver and
renal injury, and in various inflammatory conditions and
infectious disease [1].
PET-CT is increasingly used for staging of melanoma
patients. With its combination of metabolic and mor-
phologic information, PET-CT has high accuracy for
metastases and is superior to CT or MRI alone [6]. Sen-
sitivity is highest (≥90%) for metastases that are > 1 cm
in diameter, but tumour deposits as small as 0.6 cm can
be seen in areas of low background activity. It is
believed that PET-CT is most useful for identifying all
metastatic sites of melanoma before deciding on opera-
tion of an apparently isolated lesion [7].
In Slovenia, a country with a population of two mil-
lion, the prevalence of CM was 1302 male and 1920
female patients in December 2009. All patients with
stage III and IV CM and a proportion of patients with
stage I and II melanoma are engaged in regular follow-
up at the Institute of Oncology Ljubljana, the only com-
prehensive cancer centre in the country.
The aims of this study were to determine whether reg-
ular measurements of serum S100B are a useful tool for
discovering patients with CM metastases and to evaluate
the diagnostic value of subsequent PET-CT during the
follow-up.
Methods
Patients
From September 2007 to February 2010, 115 patients
(45 female and 70 male) with CM were directed to
extended whole body PET-CT, based on clinical signs of
recurrent disease, increased serum S100B or both. All
patients were engaged in a regular follow-up at the
Institute of Oncology Ljubljana after being diagnosed
with CM. Clinical stage of the patients at the time of
diagnosis of CM was classified according to American
Joint Committee on Cancer (AJCC) criteria. Most
patients were diagnosed with localized stage I and II of
CM (21 or 18.3% and 47 or 40.9% respectively), but 40
(34.8%) of patients were stage III and 5 (4.3%) were
stage IV at the time of diagnosis. For two patients
(1.7%) stage of the disease at the time of diagnosis could
not be assessed reliably.
Initially 33 (28.7%) patients were treated only by wide
excision, 39 (33.9%) patients with wide excision and sen-
tinel node biopsy, while in 40 cases (34.8%) limphade-
nectomy was performed. There was a case of locally
advanced anal melanoma treated with abdominoperineal
resection, a case of isolated limb perfusion and a patient
refusing all treatment after initial excision. Three
patients diagnosed with stage IV disease received dacar-
bazine and two patients received only symptomatic
treatment. All patients were followed at regular inter-
vals, i.e. every 3 months in the first and second year
after the diagnosis, every 6 months in the third to fifth
year, and once a year after first 5 years. Patients were
monitored at each visit for relapse by history, physical
examination and laboratory tests including S100B. Dis-
ease progression was suspected based on clinical signs
in 82 (71.3%) patients and based on increased S100B in
33 (28.7%) asymptomatic patients. There were 25
(21.7%) patients with both, increased S100B and clinical
signs of advancing disease. In majority of patients
(34.8%, 40/115) skin metastases were the first sign of
progression. Twenty-four patients (20.9%) had palpable
lymph nodes, 2.6% complained of persistent cough (3/
115), 9.6% (11/115) of pain and in two cases (1.7%) mild
gastro intestinal bleeding was present. In two patients,
accidental radiological findings could not be ruled out
as CM metastases by treating physicians. Mean time at
which PET-CT followed measurement of serum S100B
was 21.19 days.
All patients were informed about the research proto-
col and signed a consent form. The study was reviewed
and approved by institutional Ethics Committee.
S100B
Serum concentrations of S100B (heterodimers S100 A1B
and S100 BB) were determined by the use of the elec-
trochemiluminescence immunoassay (ECLIA). The
immunoassays were analyzed on the Modular Analytics
E170 immunoassay analyzer (Roche Diagnostics). Refer-
ence values were obtained from apparently healthy
volunteers: 0.105 μg/L was determined as the upper nor-
mal value (Roche Diagnostics). In cases of increased
tumour marker values, sampling and determination of
the serum S100B were repeated for confirmation after
two weeks. Only patients with elevated repeated values
were appointed to subsequent PET-CT scan.
PET-CT scan
Extended whole body PET-CT scan was performed in
cases where distant metastases were suspected due to
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ease. The scans were performed after a six-hour fast and
when the patients were prepared according to recom-
mendations (EANM guidelines) [8]. A hybrid PET/CT
camera Philips Gemini GXL was used and FDG was
administrated in dosage of 5.18 MBq (0.14 mCi)/kg
body weight. The interval between FDG administration
and scanning was 60 minutes ± 10 minutes. Low-dose
CT images were obtained (150 mAs, 3 mm slices) with-
out oral or intravenous contrast. Acquired images were
viewed using a Brilliance and Medic View 3D display.
PET was fused to low-dose CT after correction for
attenuation. The PET-CT scans were reviewed by an
experienced nuclear medicine physician. The presence
of abnormal FDG accumulation in the images in combi-
nation with their size and intensity was evaluated.
Under normal circumstances a standard uptake value
(SUV) of 2.5 was considered normal.
Statistics
The McNemar symmetry chi square test was used to
compare performance of the S100B with that of PET-
CT. Sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) of S100B and
PET-CT were calculated using standard procedures.
Separate analyses were made for patients with no clini-
cal signs of the disease and for patients with CM stage I
and II at the time of diagnosis. All statistical analyses
were performed using the Statistical Package for Social
Sciences (SPSS) for Windows version 15.0.
Results
115 patients suspected of disease progression based on
clinical signs (82, 71.3%) and/or increased levels of
serum S100B (33, 28.7%) were appointed to extended
whole body PET-CT at the Institute of Oncology
Ljubljana from 2007 until the beginning of 2010. The
mean age of the patients at the time PET-CT was per-
formed was 60.8 (ranged from 16.3 to 86.8) years. The
group comprised of 39.1% female and of 60.9% male
patients.
Out of 115 patients, disease progression was diagnosed
in 94 (81.7%) patients. Metastases were confirmed by
fine needle aspiration cytology in 34 (36.2%), with CT or
MRI in 11 cases (11.7%), with ultrasound or radiological
finding in 11 cases (11.7%) and based on the histology
report in 38 cases (40.4%) prior to implementation of
appropriate treatment.
As far as the rest of the patients are concerned, there
were 3 patients with palpable lymph nodes, 6 patients
with pain and 2 patients with suspicious radiological
findings, however the metastases could not be con-
firmed. Altogether 21 patients proved to be disease free
at that time (18.3%).
The majority of patients with skin metastases (distant
and in transit included) had normal level of S100B.
Patients with lymph node metastases had increased
S100B in 50.0% of cases compared to 57.1% of patients
with distant visceral metastases (Table 1). Table 1 shows
location of discovered metastases and results of S100B
measurements for all 115 patients.
Out of 82 patients with suspicious clinical signs,
metastases were confirmed in 71 (86.5%). The majority
of these patients did not have increased values of serum
S100B (47/71, 66.2%). In eleven patients presented with
clinical signs, metastases were not discovered.
Symptomatic patients had elevated S100B levels in
30.5% of cases (25/82). The mean value of S100B marker
in that group of patients was 0.603 μg/L (median value
0.228 μg/L). For symptomatic patients without increased
S100B, the mean value of serum marker was 0.051 μg/L
(median value 0.046 μg/L). In 33 patients without clinical
signs of disease progression, the mean value of S100B
was 0.652 μg/L (median value 0.255 μg/L).
In 33 patients with no symptoms but with an
increased S100B, metastatic disease was confirmed in
twenty three patients (69.7%) and 10 patients were
healthy. Based solely on increased S100B, metastases
were discovered in 20.0% (23/115) of all cases.
The PET-CT pointed out suspicious lesions in 95/115
(82.6%) patients. In 20 (17.4%) patients PET-CT was
negative. False positive results with SUV 15.2 and 8.0
were obtained in two patients. Metastases were actually
confirmed in 94 (81.7%) out of 115 patients. The c
2
value for McNemar test comparing S100B and PET-CT
was 21.9 with p < 0.0001 respectively.
Patients with normal S100B level but suspicious clini-
cal signs, had metastases diagnosed with PET-CT in
84.2% of cases (48/57). Disease progression was later
actually confirmed in 47 of those patients. In 9 cases
PET-CT was negative and patients were proved to be
disease free.
If patients had increased S100B level (58 patients, 25
with symptoms and 33 without), PET-CT diagnosed
suspicious lesions in 47 (81.0%) cases. In 11 cases with
increased S100B, PET-CT was negative. In only one of
those cases metastases were present later on follow-up.
Out of 33 asymptomatic patients with increased S100B
suspicious lesions were diagnosed in 72.7% of cases.
Based on those results 98.9% sensitivity, 90.4% specifi-
city, 97.8% PPV and 95.0% NPV of PET-CT was calcu-
lated for the whole group of patients (Table 2).
Analysis was repeated for 68 patients with localized
disease (stage I or II) at the time of the first visit. In 54/
68 patients disease progression was confirmed during
the follow-up. Among 48 patients with clinical signs of
disease progression, there were 15 (31.2%) individuals
where S100B was also increased. In majority of patients
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83.3%).
Table 3 presents specificity, sensitivity and predictive
values for patients with localized disease.
Discussion
Since the prognosis of patients with CM is determined
by the extent of metastatic disease, serum biomarker
and imaging studies using radiographic and nuclear
medicine techniques are an important component of
patient evaluation [7].
Almost 10 years ago researchers suggested that mea-
suring S100B after primary local surgical therapy may
allow early recognition of disease progression. It was
also suggested that an increasing S100B, followed by a
positive emission tomography (PET) scan and appropri-
ate treatment, could lead to an increased life expectancy
of patients with CM [9]. Despite being shown, that
S100B levels correlate with disease staging, the extent of
metastatic spread and disease progression, the value of
it’s measuring in follow-up is still controversial. This is
true especially for early stages of the disease. The diag-
nostic sensitivity of serum S100B in patients with stage I
and II CM has been reported to be 15% or less com-
pared to 60-85% sensitivity for stage IV CM. For
patients with regional metastases, sensitivity varies from
10% to 50% [1,7].
We analyzed a group of 115 patients appointed to
PET-CT due to increased serum S100B value (33 pts) or
clinical signs of disease progression encountered during
regular follow-up (82 pts). In our study patients with
stage I or II of CM had 51.8% sensitivity and 50.0% spe-
cificity of S100B. PPV of S100B for this group of
patients was 80.0% and NPV was only 21.2%. A similar
study conducted in 2002 showed sensitivity between 3%
and 9% for stage I and II. The study described a PPV of
17% for stage I and 37% for stage II and specificity was
92%. Based on that, the authors concluded that S100B
could not be a reliable marker of disease dissemination
at early stages [10].
The sensitivity of increased serum S100B for the
whole group of patients (115 pts) regardless of the stage
of the disease in our study was 50.0%, specificity 47.6%,
PPV 81.0% and NPV 17.5%. In studies which included
patients with clinical symptoms being either present or
absent the sensitivity was 38% with PPV 93% and 37%
respectively [10,11]. Our results for the whole group of
patients did not differ much from the results for the
group of patients with stage I or II, which could indicate
that successful use of marker is not conditioned by the
Table 1 Confirmed location of CM metastases and value of serum S100B
Metastases
Increased serum S100B Skin
(%)
Regional lymph nodes (%) Distant visceral
(%)
Absent
(%)
Yes 8 (34.8) 11 (50.0) 28 (57.1) 11 (52.4)
No 15 (65.2) 11 (50.0) 21 (42.9) 10 (47.6)
Total 23 22 49 21
Table 2 Sensitivity, specificity, PPV and NPV of serum S100B and PET-CT
All pts
(115)
PPV %
(N)
NPV %
(N)
Sensitivity % (N) Specificity % (N)
S100B 81.0 (47/58) 17.5 (10/57) 50.0 (47/94) 47.6 (10/21)
PET-CT 97.8 (93/95) 95.0 (19/20) 98.9 (93/94) 90.4 (19/21)
Pts with clin. sign
(82)
PPV %
(N)
NPV %
(N)
Sensitivity % (N) Specificity % (N)
S100B 96.0 (24/25) 17.5 (10/57) 33.8 (24/71) 90.9 (10/11)
PET-CT 98.5 (70/71) 90.9 (10/11) 98.5 (70/71) 90.9 (10/11)
Asymptomatic pts
(33)
PPV %
(N)
NPV %
(N)
Sensitivity % (N) Specificity % (N)
S100B 69.7 (23/33) 0 bias 100.0 (23/23) 0 bias
PET-CT 95.8 (23/24) 100.0 (9/9) 100.0 (23/23) 90.0 (9/10)
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test in British study was 74% and 87% with PPV of 87%
and NPV of 76% for the group of patients regardless of
the stage of CM. They suggested that S100B may accu-
rately reflect the activity of the disease at the sampling
time. The surprising finding of that study was, that the
conclusion is not true in the presence of cerebral metas-
tases even if additional organs were involved [12].
It has been observed by other authors that location of
the metastases influences the level of S100B. Authors
report that between 41 to 68% of patients with stage III
disease do not have an increased serum marker [11,13-15].
In our study 50.0% of patients with metastases limited to
the lymph nodes and 42.9% of patients with distant metas-
tases did not have the increased level of serum marker.
The result could be a consequence of a smaller tumour
burden in the case of stage III disease as it has been pro-
posed by others [13,15]. Another possibility would be that
primary tumours have different expression patterns of
protein S100B. In the case of the metastatic disease, serum
levels would depend on the ability of CM cells to produce
a serum marker, which would explain false negative results
in the case of distant metastases [12,13].
Comparing increased levels of serum S100B from
different studies has one major obstacle, namely research-
ers are using different immunoassays with slightly different
cut off values of serum S100B. Different assays used in
clinical practice were compared and it was determined
that the correlation among assays is satisfactory with cor-
relation index of 0.9 or higher for most assays. Neverthe-
less, data from the assays using bovine brain solution and
those standardized against human recombinant S100B can
not be superimposed. Difficulties are also encountered
comparing upper cut off values ranging from 0.09 to 0.13
μg/l, which indicates the need for international agreement
regarding the use of uniform reference standards for suc-
cessful comparison of different studies [16].
All patients in our study were appointed to extended
whole body PET-CT. Eleven patients (11/115, 9.5%) had
increased level of S100B, but no metastases were proven
on PET-CT or by clinical follow up. The number of
reported false positive results of S100B in other studies
ranges from 17 to 41% of cases [15]. There are few pos-
sible explanations for false positive results. Elevated
levels of S100B had been observed after head trauma
and stroke and can reflect a brain injury or dysfunction
of blood-brain barrier. Significantly higher serum levels
can be found in patients with liver cirrhosis or renal fail-
ure [15]. Interestingly 25% of healthy individuals can
also have an increased S100B level, the fact that could
be explained by an increased serum S100B level mea-
sured after UVB exposure of some individuals [17].
The main limitation of our study is that patients were
appointed to PET-CT based on the increased S100B or
clinical suspicion of disease progression which repre-
sents a selection bias influencing NPV and specificity of
S100B. Published retrospective studies also describe
groups of patients inspected with PET-CT due to
increased S100B and report similar bias [15]. Our group
of patients was chosen because we were interested in
clinical value of S100B measurements in conjunction
with PET-CT during regular follow up. A study pub-
lished by Aukema concentrated on patients with normal
findings at physical examination and increased serum
S100B level. At the cut off value similar to one used by
us, PPV of the S100B was reported to be 50%. The PPV
Table 3 Sensitivity, specificity, PPV and NPV of serum S100B and PET-CT for patients with stage I or II
Pts with stage I or II
(68)
PPV %
(N)
NPV%
(N)
Sensitivity% (N) Specificity% (N)
S100B 80.0% (28/35) 21.2% (7/33) 51.8% (28/54) 50.0% (7/14)
PET-CT 98.2% (54/55) 100.0% (13/13) 100.0% (54/54) 92.8% (13/14)
With clin. sign
(48)
PPV%
(N)
NPV%
(N)
Sensitivity% (N) Specificity% (N)
S100B 93.3 (14/15) 21.3 (7/33) 65.0 (26/40) 87.5 (7/8)
PET-CT 97.5 (40/41) 100.0 (7/7) 100.0 (40/40) 87.5 (7/8)
Asymptomatic pts
(20)
PPV%
(N)
NPV%
(N)
Sensitivity% (N) Specificity% (N)
S100B 70.0 (14/20) 0 bias 100.0 (14/14) 0 bias
PET-CT 100.0 (14/14) 100.0 (6/6) 100.0 (14/14) 100.0 (6/6)
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both studies prove a serum measurement of S100B as a
helpful but not perfect method for follow up of all CM
patients [18].
The sensitivity of PET-CT in our study was 98.9% with
90.4% specificity for the whole group of patients and
100% with 90.0% specificity if clinical signs were absent.
The accompanying PPV was 97.8% in the first group and
95.8% in the subgroup of patients. Aukema reported a
sensitivity of 100%, specificity of 83%, PPV of 85% and
NPV of 100% [18]. The role of PET-CT in the manage-
ment of patients with CM evolved rapidly. It has been
shown, that PET-CT enables more accurate staging of
distant metastases than PET or CT alone (98% compared
to 93% and 84% respectively), and is more accurate in
diagnosing lymph node metastases (98% compared to
86%) [7,15]. Diagnosing metastases with PET-CT is over-
all more accurate then CT or MRI alone and at the same
time provides valuable information to the surgeon plan-
ning an operative procedure [7,18]. Out of 95 patients
being diagnosed with suspicious lesions on PET-CT, two
proved to be a false positive (2.1%). Other authors also
report false positive results [15,18]. In our study one false
positive result was a case of lesion with diameter of 1 cm
suspected to be a metastasis. It has been stated in a
recent report describing staging of CM that sensitivity of
PET-CT is highest for metastases that are > 1 cm in dia-
meter and it is recognized that in the case of melanoma,
the sensitivity of the method declines when the diameter
of tumour is less then 6 mm [7,8]. In the second false
positive PET-CT result, careful examination of the
patient’s record revealed a chronic wound at the location
of the increased FDG uptake. It is known that increased
uptake is observed not only in neoplastic lesions but also
in granulation tissue, infection and other inflammatory
processes. In order to use PET-CT successfully it is
necessary to evaluate the size and intensity of abnormal
FDG focal accumulation with patients history and physi-
cal examination [8].
Due to short follow-up, we did not investigate how the
outcome of regular measurements of serum S100B and
subsequent PET-CT influences overall survival of our
patients. It is known that increased S100B levels are
related to prognosis and survival of patients with CM. A
meta-analysis of twenty-two articles published until 2008
proved S100B as an independent prognostic factor of sur-
vival with special regard to stage I-III patients [5]. In
advanced disease elevated levels of S100B also demon-
strate a strong correlation with reduced survival as
patients with stage III or IV disease and low S100B have
shown statistically significant survival advantage compared
to patients with elevated tumour marker [1,15]. Whether
PET-CT can act as an independent prognostic factor
remains to be elucidated [15].
We confirmed metastases in 20.0% of patients based
on the increased serum S100B as the only preceding
sign of disease progression (23/115). Since the analysis
of serum S100B showed the highest sensitivity and
specificity of all tumour markers examined in CM and
it is fairly inexpensive, numerous clinicians include its
measurement in routine follow up of CM patients
[7,19]. In the case of disease progression monitoring,
rising level of serum S100B is believed to be a specific
and sensitive marker of disease relapse that can detect
metastases 5-23 weeks before other clinical and radi-
ological methods. During routine follow-up, elevated
S100B levels were noted 6 months before ultrasound
and chest X-ray were able to detect disseminated
disease [1]. Serum S100B can be used as a marker of
disease progression which together with subsequent
PET-CT enables clinicians early diagnosis of metas-
tases during regular follow-up.
If there is an actual benefit of carefully planned follow-
up schedules for CM patients remains to be elucidated. A
study conducted by German researchers proved a gain in
survival time for the detection of metastasis at an early
phase of development beyond the effect of lead time bias.
Namely the 10-year overall survival probability was
increased significantly for patients with early phase
metastases [20].
Conclusion
Measurements of serum S100B during regular follow-up
of patients with CM are a useful tool for discovering dis-
ease progression in asymptomatic patients. This applies
equally to patients with localized disease (stage I and II) as
to patients with stage III or IV. The value of its use
increases if measurements are followed by extended whole
body PET-CT. If the approach described in our study has
any influence on patients’ survival will be validated in the
future.
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